<DOC>
	<DOC>NCT00185198</DOC>
	<brief_summary>The purpose of this study is to investigate the effect of a testosterone replacement therapy called Testogel in men with PADAM. The effects on body composition (lean, fat and bone) and other symptoms of PADAM and safety will be studied.</brief_summary>
	<brief_title>Efficacy and Safety of TestogelÂ® in Men With Partial Androgen Deficiency of Aging Males (PADAM)</brief_title>
	<detailed_description>The study has previously been posted by Schering AG, Germany. Schering AG, Germany has been renamed to Bayer Schering Pharma AG, Germany. Bayer Schering Pharma AG, Germany is the sponsor of the trial.</detailed_description>
	<mesh_term>Testosterone</mesh_term>
	<mesh_term>Testosterone enanthate</mesh_term>
	<mesh_term>Testosterone undecanoate</mesh_term>
	<mesh_term>Testosterone 17 beta-cypionate</mesh_term>
	<mesh_term>Androgens</mesh_term>
	<mesh_term>Methyltestosterone</mesh_term>
	<criteria>Symptomatic hypogonadism Willing to avoid significant change in the pattern of physical exercise and lifestyle for the duration of the study Patients with any contraindication for testosterone use</criteria>
	<gender>Male</gender>
	<minimum_age>50 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>April 2014</verification_date>
	<keyword>Partial androgen deficiency of aging males (PADAM)</keyword>
</DOC>